Literature DB >> 27347061

Bushen-Qiangdu-Zhilv decoction inhibits osteogenic differentiation of rat fibroblasts by regulating connexin 43.

Ying-Yan Zhou1, Run-Yue Huang2, Jie-Hua Lin1, Yong-Yue Xu1, Xiao-Hong He2, Yi-Ting He3.   

Abstract

Bushen-Qiangdu-Zhilv (BQZ) decoction is a traditional Chinese medicinal compound widely used for treating ankylosing spondylitis (AS). However, the mechanisms underlying effects of BQZ remain largely unknown. Osteoblast differentiation of fibroblasts plays an important role in heterotopic ossification (HO) of AS, and connexin 43 (Cx43) is crucially involved in the osteoblast differentiation of fibroblasts. The aim of the present study was to evaluate the effects of BQZ on the osteogenic differentiation of fibroblasts by regulating Cx43. Rat fibroblasts were treated with freeze-dried powder of BQZ, in the presence or absence of recombinant human bone morphogenetic protein-2 (rhBMP-2). MTS assays were performed to examine the inhibitory effects of BQZ on fibroblast proliferation. Western blot assays were conducted to detect the protein expression of core-binding factor alpha 1 (Cbfα1), Cx43 and phosphorylated Cx43 (pCx43). BQZ appeared to inhibit fibroblast proliferation in a dose-dependent manner. Furthermore, the expression of Cbfα1 and Cx43/pCx43 was significantly suppressed by BQZ, with or without rhBMP-2 stimulation. Therefore, the present results indicate that BQZ may exert an anti-AS effect by suppressing the osteogenic differentiation of fibroblasts via Cx43 regulation.

Entities:  

Keywords:  ankylosing spondylitis; connexin 43; fibroblasts; osteogenic differentiation

Year:  2016        PMID: 27347061      PMCID: PMC4906848          DOI: 10.3892/etm.2016.3292

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  31 in total

1.  Bone morphogenetic protein-transduced human fibroblasts convert to osteoblasts and form bone in vivo.

Authors:  R Bruce Rutherford; Maria Moalli; Renny T Franceschi; Dian Wang; Keni Gu; Paul H Krebsbach
Journal:  Tissue Eng       Date:  2002-07

2.  The transcriptional activity of osterix requires the recruitment of Sp1 to the osteocalcin proximal promoter.

Authors:  Corinne Niger; Florence Lima; David J Yoo; Rishi R Gupta; Atum M Buo; Carla Hebert; Joseph P Stains
Journal:  Bone       Date:  2011-07-28       Impact factor: 4.398

Review 3.  Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.

Authors:  Cécile Escalas; Sophie Trijau; Maxime Dougados
Journal:  Rheumatology (Oxford)       Date:  2010-04-01       Impact factor: 7.580

4.  Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.

Authors:  L E Kristensen; A K Jakobsen; J Askling; F Nilsson; L T H Jacobsson
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-08       Impact factor: 4.794

5.  Celecoxib suppresses fibroblast proliferation and collagen expression by inhibiting ERK1/2 and SMAD2/3 phosphorylation.

Authors:  Fengfeng Li; Cunyi Fan; Bingfang Zeng; Changqing Zhang; Yimin Chai; Shen Liu; Yuanming Ouyang
Journal:  Mol Med Rep       Date:  2011-12-19       Impact factor: 2.952

6.  Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor beta1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation.

Authors:  M H Lee; A Javed; H J Kim; H I Shin; S Gutierrez; J Y Choi; V Rosen; J L Stein; A J van Wijnen; G S Stein; J B Lian; H M Ryoo
Journal:  J Cell Biochem       Date:  1999-04-01       Impact factor: 4.429

7.  Canine oral mucosal fibroblasts differentiate into osteoblastic cells in response to BMP-2.

Authors:  Kohsuke Umehara; Tadahiro Iimura; Kei Sakamoto; Zayar Lin; Shohei Kasugai; Yoshimasa Igarashi; Akira Yamaguchi
Journal:  Anat Rec (Hoboken)       Date:  2012-06-07       Impact factor: 2.064

8.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

9.  Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis.

Authors:  M-C Park; Y-B Park; S-K Lee
Journal:  Scand J Rheumatol       Date:  2008 May-Jun       Impact factor: 3.641

10.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

View more
  2 in total

1.  MicroRNA‑204‑5p inhibits the osteogenic differentiation of ankylosing spondylitis fibroblasts by regulating the Notch2 signaling pathway.

Authors:  Jianjun Zhao; Yanyan Zhang; Bo Liu
Journal:  Mol Med Rep       Date:  2020-07-06       Impact factor: 2.952

2.  Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial.

Authors:  Zhang Wang; Jiaqi Wu; Dongyun Li; Xuan Tang; Yue Zhao; Xiao Cai; Xianghong Chen; Xiumin Chen; Qingchun Huang; Runyue Huang
Journal:  Chin Med       Date:  2020-04-23       Impact factor: 5.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.